# Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05473624/  
OnCo record `nct05473624` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT05473624 as recruiting, last updated 2025-04-15. Enrolment is 153 planned participants, an estimate. Interventions: HRS-1167. Primary measures include Dose-limiting toxicity (DLT) of HRS-1167; Maximum tolerated dose (MTD) of HRS-1167. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT05473624
- Phase: 1
- Setting: A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.

## Sources

- ClinicalTrials.gov NCT05473624: https://clinicaltrials.gov/study/NCT05473624

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HRS-1167](https://onco.cc/drugs/hrs-1167/)

---
JSON: https://onco.cc/api/v1/entities/nct05473624.json